{"id":"NCT00441545","sponsor":"Shire","briefTitle":"Head to Head Study Against Sevelamer Hydrochloride","officialTitle":"A Prospective, Multicenter, Open-label, Randomized, Cross-over Study to Compare the Efficacy and Safety of FosrenolÂ® and Sevelamer Hydrochloride in Patients Receiving Hemodialysis for End Stage Renal Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01-05","primaryCompletion":"2008-07-31","completion":"2008-07-31","firstPosted":"2007-03-01","resultsPosted":"2009-08-13","lastUpdate":"2021-06-11"},"enrollment":182,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease, Stage 5"],"interventions":[{"type":"DRUG","name":"Fosrenol (Lanthanum Carbonate)","otherNames":["FOSRENOL"]},{"type":"DRUG","name":"Sevelamer hydrochloride","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the efficacy of Fosrenol (Lanthanum carbonate) and sevelamer hydrochloride in the reduction of serum phosphorus levels from baseline.","primaryOutcome":{"measure":"Change From Baseline in Serum Phosphorus Levels at 4 Weeks","timeFrame":"4 weeks","effectByArm":[{"arm":"Fosrenol","deltaMin":-1.73,"sd":0.129},{"arm":"Sevelamer HCl","deltaMin":-1.44,"sd":0.132}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1130"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":44,"countries":["United States","Germany","Puerto Rico","United Kingdom"]},"refs":{"pmids":["19825330","40576086"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":170},"commonTop":["Nausea","Diarrhea","Vomiting"]}}